Potentiated DNA damage response in circulating breast tumor cells confers resistance to chemotherapy

Journal of Biological Chemistry

Volumn 290, Issue 24, 2015, Pages 14811-14825

  Gong, Chang ^a   Liu, Bodu ^a   Yao, Yandan ^a   Qu, Shaohua ^a   Luo, Wei ^a   Tan, Weige ^a   Liu, Qiang ^a   Yao, Herui ^b   Zou, Lee ^c   Su, Fengxi ^a   Song, Erwei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; DNA; PATHOLOGY; TUMORS;

BREAST CANCER; BREAST TUMOR CELLS; CANCER METASTASIS; CHEMORESISTANCE; CIRCULATING TUMOR CELLS; DNA DAMAGE RESPONSE; EXTRACELLULAR MATRICES; REACTIVE OXYGEN SPECIES;

DISEASES;

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHIR 124; CHK2 INHIBITOR II; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PACLITAXEL; PROTEIN SERINE THREONINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA DAMAGE RESPONSE; DNA REPAIR; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR XENOGRAFT; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84931287685     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.652628     Document Type: Article

References (48)

1. Wang, M. W., Wang, F., Zheng, Y. J., Zhang, Y. J., Zhang, Y. P., Zhao, Q., Shen, C. K., Wang, Y., and Sun, S. H. (2013) An in vivo molecular imaging probe (18) F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation. Apoptosis 18, 238-247
2. Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., Ryan, P., Balis, U. J., Tompkins, R. G., Haber, D. A., and Toner, M. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239
3. Alix-Panabieres, C., Riethdorf, S., and Pantel, K. (2008) Circulating tumor cells and bone marrow micrometastasis. Clin. Cancer Res. 14, 5013-5021
4. Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., and Massague, J. (2009) Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326
5. Maheswaran, S., and Haber, D. A. (2010) Circulating tumor cells: a window into cancer biology and metastasis. Curr. Opin. Genet. Dev. 20, 96-99
6. Boldin, M. P., and Baltimore, D. (2012) MicroRNAs, new effectors and regulators of NF-kB. Immunol. Rev. 246, 205-220
7. Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W., and Hayes, D. F. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl. J. Med. 351, 781-791
8. Bi, H. S., Yang, X. Y., Yuan, J. H., Yang, F., Xu, D., Guo, Y. J., Zhang, L., Zhou, C. C., Wang, F., and Sun, S. H. (2013) H19 inhibits RNA polymerase II-mediated transcription by disrupting the hnRNP U-actin complex. Biochim. Biophys. Acta 1830, 4899-4906
9. De Giorgi, U., Valero, V., Rohren, E., Dawood, S., Ueno, N. T., Miller, M. C., Doyle, G. V., Jackson, S., Andreopoulou, E., Handy, B. C., Reuben, J. M., Fritsche, H. A., Macapinlac, H. A., Hortobagyi, G. N., and Cristofanilli, M. (2009) Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 27, 3303-3311
10. Negin, B. P., and Cohen, S. J. (2010) Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr. Treat Options Oncol. 11, 1-13
11. Krebs, M. G., Sloane, R., Priest, L., Lancashire, L., Hou, J. M., Greystoke, A., Ward, T. H., Ferraldeschi, R., Hughes, A., Clack, G., Ranson, M., Dive, C, and Blackhall, F. H. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol. 29, 1556-1563
12. De Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W., Pienta, K. J., and Raghavan, D. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309
13. Rack, B., Schindlbeck, C., Juckstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W., Lorenz, R., Tesch, H., Fasching, P. A., Fehm, T., Schneeweiss, A., Lichtenegger, W., Beckmann, M. W., Friese, K., et al. (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst. 10.1093/jnci/dju066
14. Hong, J. P., Sun, S. H., and Ben-Nakhi, M. (2013) Modified superficial circumflex iliac artery perforator flap and supermicrosurgery technique for lower extremity reconstruction: a new approach for moderate-sized defects. Ann. Plast. Surg. 71, 380-383
15. Barbazan, J., Alonso-Alconada, L., Muinelo-Romay, L., Vieito, M., Abalo, A., Alonso-Nocelo, M., Candamio, S., Gallardo, E., Fernandez, B., Abdulkader, I., De Los Angeles Casares, M., Gomez-Tato, A., Lopez-Lopez, R., and Abal, M. (2012) Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PLoS ONE 7, e40476
16. Iwatsuki, M., Toyoshima, K., Watanabe, M., Hayashi, N., Ishimoto, T., Eto, K., Iwagami, S., Baba, Y., Yoshida, N., Hayashi, A., Ohta, Y., and Baba, H. (2013) Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br. J. Cancer 109, 2829-2832
17. Hayashi, N., Nakamura, S., Tokuda, Y., Shimoda, Y., Yagata, H., Yoshida, A., Ota, H., Hortobagyi, G. N., Cristofanilli, M., and Ueno, N. T. (2012) Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int. J. Clin. Oncol. 17, 96-104
18. Wan, Y., and Chang, H. Y. (2010) HOTAIR: flight of noncoding RNAs in cancer metastasis. Cell Cycle 9, 3391-3392
19. Gingery, A., Bradley, E., Shaw, A., and Oursler, M. J. (2003) Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkB pathways to maintain osteoclast survival. J. Cell. Biochem. 89, 165-179
20. Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., and Fehm, T. (2012) Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 14, R15
21. Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., Wittner, B. S., Stojanov, P., Brachtel, E., Sgroi, D., Kapur, R., et al. (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216-220
22. Zhong, X., and Rescorla, F. J. (2012) Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell. Signal. 24, 393-401
23. Schafer, Z. T., Grassian, A. R., Song, L., Jiang, Z., Gerhart-Hines, Z., Irie, H. Y., Gao, S., Puigserver, P., and Brugge, J. S. (2009) Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461, 109-113
24. Ozkumur, E., Shah, A. M., Ciciliano, J. C., Emmink, B. L., Miyamoto, D. T., Brachtel, E., Yu, M., Chen, P. I., Morgan, B., Trautwein, J., Kimura, A., Sengupta, S., Stott, S. L., Karabacak, N. M., Barber, T. A., et al. (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci. Transl. Med. 5, 179ra47
25. Howard, E. W., Leung, S. C., Yuen, H. F., Chua, C. W., Lee, D. T., Chan, K. W., Wang, X., and Wong, Y. C. (2008) Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer. Clin. Exp. Metastasis 25, 497-508
26. Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., Huang, Y., Hu, X., Su, F., Lieberman, J., and Song, E. (2007) let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123
27. Rossi, E., Fassan, M., Aieta, M., Zilio, F., Celadin, R., Borin, M., Grassi, A., Troiani, L., Basso, U., Barile, C., Sava, T., Lanza, C., Miatello, L., Jirillo, A., Rugge, M., et al. (2012) Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br. J. Cancer 107, 1286-1294
28. Ksiązkiewicz, M., Markiewicz, A., and Zaczek, A. J. (2012) Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 79, 195-208
29. Hirschmann-Jax, C., Foster, A. E., Wulf, G. G., Nuchtern, J. G., Jax, T. W., Gobel, U., Goodell, M. A., and Brenner, M. K. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 101, 14228-14233
30. Alagoz, M., Gilbert, D. C., El-Khamisy, S., and Chalmers, A. J. (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers, and therapeutic targets. Curr. Med. Chem. 19, 3874-3885
31. Helleday, T. (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31, 955-960
32. Rai, P. (2010) Oxidation in the nucleotide pool, the DNA damage response and cellular senescence: defective bricks build a defective house. Mutat. Res. 703, 71-81
33. Nguyen, D. X., Bos, P. D., and Massagué, J. (2009) Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284
34. Pilati, P., Mocellin, S., Bertazza, L., Galdi, F., Briarava, M., Mammano, E., Tessari, E., Zavagno, G., and Nitti, D. (2012) Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann. Surg. Oncol. 19, 402-408
35. Avivar-Valderas, A., Salas, E., Bobrovnikova-Marjon, E., Diehl, J. A., Nagi, C., Debnath, J., and Aguirre-Ghiso, J. A. (2011) PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment. Mol. Cell. Biol. 31, 3616-3629
36. Ravid, A., Rocker, D., Machlenkin, A., Rotem, C., Hochman, A., Kessler-Icekson, G., Liberman, U. A., and Koren, R. (1999) 1, 25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 59, 862-867
37. Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., Joshua, B., Kaplan, M. J., Wapnir, I., Dirbas, F. M., Somlo, G., et al. (2009) Association of reactive oxygen species levels and radioresistancein cancer stem cells. Nature 458, 780-783
38. Sherman, M. H., Bassing, C. H., and Teitell, M. A. (2011) Regulation of cell differentiation by the DNA damage response. Trends Cell Biol. 21, 312-319
39. Park, Y. Y., Jung, S. Y., Jennings, N. B., Rodriguez-Aguayo, C., Peng, G., Lee, S. R., Kim, S. B., Kim, K., Leem, S. H., Lin, S. Y., Lopez-Berestein, G., Sood, A. K., and Lee, J. S. (2012) FOXM1 mediates Dox resistancein breast cancer by enhancing DNA repair. Carcinogenesis 33, 1843-1853
40. Tobin, L. A., Robert, C., Nagaria, P., Chumsri, S., Twaddell, W., Ioffe, O. B., Greco, G. E., Brodie, A. H., Tomkinson, A. E., and Rassool, F. V. (2012) Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol. Cancer Res. 10, 96-107
41. Xu, Y., and Price, B. D. (2011) Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle 10, 261-267
42. Poehlmann, A., and Roessner, A. (2010) Importance of DNA damage checkpoints inthe pathogenesis ofhuman cancers. Pathol. Res. Pract. 206, 591-601
43. Al-Ejeh, F., Kumar, R., Wiegmans, A., Lakhani, S. R., Brown, M. P., and Khanna, K. K. (2010) Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 29, 6085-6098
44. Dai, Y., and Grant, S. (2010) New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16, 376-383
45. Ashwell, S., Janetka, J. W., and Zabludoff, S. (2008) Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin. Investig. Drugs 17, 1331-1340
46. Ma, C. X., Ellis, M. J., Petroni, G. R., Guo, Z., Cai, S. R., Ryan, C. E., Craig Lockhart, A., Naughton, M. J., Pluard, T. J., Brenin, C. M., Picus, J., Creekmore, A. N., Mwandoro, T., Yarde, E. R., Reed, J., et al. (2013) A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res. Treat. 137, 483-492
47. Bryant, C., Rawlinson, R., and Massey, A. J. (2014) Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer 14, 570
48. Sausville, E., Lorusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., Zabludoff, S., Agbo, F., Oakes, P., and Senderowicz, A. (2014) Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in United States patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 539-549